India Pharma Q1 Preview: Home Gains But Subdued US Growth
Leading Indian firms are expected to report revenue growth, propped by a strained domestic business in the first quarter of the last fiscal year. But it is management commentary around pricing developments in the US, a key revenue contributor for most frontline firms, and plans around specialty product introductions that are expected to be keenly tracked by investors.
You may also be interested in...
Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and more nimble. Headcount rationalization in R&D is rumored to be already underway, while more operational areas could potentially see significant manpower reductions.
Sun's Halol manufacturing facility is over the compliance hump, receiving an EIR [Establishment Inspection Report] from the US FDA. The site, seen as core to India's top ranked firm's promising filings, including injectables, is also expected to lift the prospects of Sun's spin-off R&D arm, SPARC.
Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.